HB2346 - 104th General Assembly

Rep. Laura Faver Dias

Filed: 4/8/2025

 

 


 

 


 
10400HB2346ham001LRB104 06540 BDA 24827 a

1
AMENDMENT TO HOUSE BILL 2346

2    AMENDMENT NO. ______. Amend House Bill 2346 by replacing
3everything after the enacting clause with the following:
 
4    "Section 5. The Illinois Drug Reuse Opportunity Program
5Act is amended by changing Sections 5, 45, and 55 and by adding
6Section 70 as follows:
 
7    (410 ILCS 715/5)
8    Sec. 5. Definitions. In this Act:
9    "Controlled substance" means a drug, substance, or
10immediate precursor in Schedules I through V of 21 CFR 1308.
11    "Department" means the Illinois Department of Public
12Health.
13    "Dispense" has the same meaning as defined in Section 3 of
14the Pharmacy Practice Act.
15    "Donor" means any person, including an individual member
16of the public, or any entity legally authorized to possess

 

 

10400HB2346ham001- 2 -LRB104 06540 BDA 24827 a

1medicine, including, but not limited to, a wholesaler or
2distributor, third party logistic provider, pharmacy,
3dispenser, clinic, surgical or health center, detention and
4rehabilitation center, jail, prison laboratory, medical or
5pharmacy school, prescriber or other health care professional,
6long-term care facility, or healthcare facility. "Donor"
7includes government agencies and entities that are federally
8authorized to possess medicine, including, but not limited to,
9drug manufacturers, repackagers, relabelers, outsourcing
10facilities, health care facilities operated by the U.S.
11Department of Veterans Affairs, and prisons.
12    "Drug" means a prescription drug, over-the-counter drug,
13or supplies needed to administer a prescription or
14over-the-counter drug.
15    "Eligible patient" means an individual:
16        (1) with a prescription for the drug, if a
17    prescription is required to dispense the drug, or who
18    reports symptoms treated by the drug if the drug is
19    over-the-counter; and
20        (2) who is registered with the drug's manufacturer in
21    accordance with federal Food and Drug Administration
22    requirements, if the registration is required to dispense
23    the drug.
24    "Manufacturer" has the same meaning as defined in Section
2515 of the Wholesale Drug Distribution Licensing Act.
26    "Pharmacist" means an individual licensed to engage in the

 

 

10400HB2346ham001- 3 -LRB104 06540 BDA 24827 a

1practice of pharmacy under the Pharmacy Practice Act or
2licensed to engage in the practice of pharmacy in another
3state.
4    "Practitioner" means a person licensed in this State to
5dispense or administer drugs or who is licensed in another
6state as a person authorized to dispense or administer drugs.
7    "Prescription drug" means any prescribed drug that may be
8legally dispensed by a pharmacy. "Prescription drug" does not
9include a drug for the treatment of cancer that can only be
10dispensed to a patient registered with the drug manufacturer
11in accordance with the federal Food and Drug Administration's
12requirements.
13    "Priority patient" means an eligible patient who is an
14Illinois resident and who is indigent, uninsured,
15underinsured, or enrolled in a public health benefits program.
16    "Recipient" means any person or entity legally authorized
17to possess medicine with a license or permit in the state in
18which the person or entity is located, including, but not
19limited to, a wholesaler or distributor, reverse distributor,
20repackager, hospital, pharmacy, or clinic.
21    "Returns processor" has the same meaning as defined in
22paragraph (18) of 21 U.S.C. 360eee. "Returns processor"
23includes, but is not limited to, a reverse distributor.
24    "Unopened tamper-evident packaging" has the same meaning
25as defined in the United States Pharmacopeia (USP) General
26Chapter 659, Packaging and Storage Requirements, including,

 

 

10400HB2346ham001- 4 -LRB104 06540 BDA 24827 a

1but not limited to, unopened unit-dose, multiple-dose,
2immediate, secondary, and tertiary packaging.
3(Source: P.A. 102-389, eff. 1-1-22.)
 
4    (410 ILCS 715/45)
5    Sec. 45. Recordkeeping requirements. When performing any
6action associated with a program under this Act or otherwise
7processing a donated drug for tax, manufacturer, or other
8credit, a recipient shall be considered to be acting as a
9returns processor and shall comply with all recordkeeping
10requirements for nonsalable nonsaleable returns under federal
11law. Records maintained under this Act may be accessed by the
12Department upon request.
13(Source: P.A. 102-389, eff. 1-1-22.)
 
14    (410 ILCS 715/55)
15    Sec. 55. Retention of records. All records required under
16this Act shall be retained in physical or electronic format
17and on or off the recipient's premises for a period of 6 years.
18Donors or recipients may contract with one another or a third
19party to create or maintain records on each other's behalf. An
20identifier, such as a serial number or bar code, may be used in
21place of any or all information required by a record or label
22pursuant to this Act if it allows for such information to be
23readily retrievable. Upon request by a State or federal
24regulatory agency, the identifier used for requested records

 

 

10400HB2346ham001- 5 -LRB104 06540 BDA 24827 a

1shall be replaced with the original information. An identifier
2shall not be used on patient labels when dispensing or
3administering a drug. Records maintained under this Act may be
4accessed by the Department upon request.
5(Source: P.A. 102-389, eff. 1-1-22.)
 
6    (410 ILCS 715/70 new)
7    Sec. 70. Program support provided by the Department.
8    (a) The Department shall:
9        (1) develop, maintain, and publish on its website
10    information regarding the names and locations of
11    pharmacies participating in the Illinois Drug Reuse
12    Opportunity Program;
13        (2) educate pharmacies in the State about the Illinois
14    Drug Reuse Opportunity Program and how to participate in
15    it voluntarily;
16        (3) develop and publish educational materials to allow
17    program participants and the Department to inform the
18    general public about the purposes and benefits of the
19    program; and
20        (4) collect information from participants and publish
21    the information in an annual report to the General
22    Assembly by December 31 of each calendar year, beginning
23    December 31, 2026.
24    (b) Pharmacy participants are required to notify the
25Department of their participation in any program under this

 

 

10400HB2346ham001- 6 -LRB104 06540 BDA 24827 a

1Act and report any data required in a format established by the
2Department.".